Navigation Links
Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Date:2/2/2009

ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that Richard Garr, CEO and President, will present at the 11th Annual BIO CEO & Investor Conference to be held on February 9-10, 2009, at the Waldorf=Astoria Hotel, New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO)

Neuralstem's presentation is scheduled for Monday, February 9, 2009 at 10:00 a.m. Eastern Time.

The presentation will be webcast live and will be available on the Investor Relations section of Neuralstem's website at www.neuralstem.com. For those who are not available to listen to the live broadcast, the call will be archived.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has entered into a collaborative agreement with Albert-Ludwigs-University, in Freiburg, Germany, to develop clinical trials for Huntington's disease.

In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
2. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
3. Neuralstem Reports Second Quarter Financial Results and Highlights
4. Neuralstem Fills Key Product Development Position
5. Neuralstem Responds to New StemCells, Inc. Lawsuit
6. Neuralstem Sues StemCells, Inc. Over New Patent
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
9. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
10. Neuralstem Shares Accepted for Trading on Amex(R)
11. The EntreTech Forum Presents... Greening Of America - The Conversion of Bio-Agriculture, Bio-Energy, and Bio-Products to Eco-Sustainable Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017   Valentin A. Pavlov, PhD ... , president and CEO of The Feinstein Institute ... analysis of how the nervous system regulates the immune ... bioelectronic medicine devices to treat disease and ... Neuroscience . The paper examines various studies ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today ... will allow more customers to receive their primers in ... or compromise in quality found with other providers. Express ... United States at no additional fee. ... routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, ...
(Date:1/14/2017)... 13, 2017  The Alliance for Safe Biologic Medicines ... FDA final guidance on biologic naming: ... in emphasizing the importance of distinct naming for all ... the benefits biosimilars will bring to patients, including new ... the portion of the Guidance dealing with suffix design ...
(Date:1/13/2017)... and Markets has announced the addition of the "Global Biopolymers Market ... ... 16.83% during the period 2017-2021. The report covers the ... 2017-2021. To calculate the market size, the report considers the revenue generated ... a a discussion of the key vendors operating in this market. ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/8/2016)... 2016 Market Research Future published a half cooked research ... Biometric Security and Service Market is expected to grow over the ... Market Highlights: ... Mobile Biometric Security and Service Market ... need of authentication and security from unwanted cyber threats. The increasing ...
Breaking Biology News(10 mins):